AnaptysBio (NASDAQ:ANAB) Reaches New 12-Month High on Analyst Upgrade

AnaptysBio, Inc. (NASDAQ:ANAB) hit a new 52-week high during mid-day trading on Wednesday after Barclays raised their price target on the stock from $78.00 to $79.00. Barclays currently has an overweight rating on the stock. AnaptysBio traded as high as $58.50 and last traded at $58.47, with a volume of 202416 shares traded. The stock had previously closed at $52.83.

A number of other equities research analysts have also recently commented on the company. UBS Group started coverage on AnaptysBio in a report on Wednesday, January 7th. They set a “buy” rating and a $70.00 price target on the stock. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Truist Financial boosted their price target on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Wall Street Zen lowered shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Wedbush reiterated an “outperform” rating and set a $50.00 price objective on shares of AnaptysBio in a research report on Monday, November 24th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $68.67.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Magda Marquet sold 11,000 shares of AnaptysBio stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $48.23, for a total value of $530,530.00. Following the sale, the director owned 9,930 shares of the company’s stock, valued at $478,923.90. The trade was a 52.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric J. Loumeau sold 12,500 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $44.86, for a total value of $560,750.00. Following the transaction, the insider owned 9,088 shares of the company’s stock, valued at $407,687.68. This represents a 57.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 156,280 shares of company stock worth $7,254,939. 33.50% of the stock is owned by corporate insiders.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Company announced a planned spin‑off of its biopharma operations into a new public company, “First Tracks Biotherapeutics,” targeted for Q2 2026 (potentially late April). Management frames the move as a value‑unlocking separation of distinct assets, which often leads to re‑rating of the parent and spun entity. AnaptysBio to Spin Off Biopharma Portfolio
• Positive Sentiment: Q4 results beat expectations: EPS $1.58 vs. consensus $0.89 and revenue $108.3M vs. $87.1M est. The beat supports the thesis that commercial/royalty streams are ramping and reduces near‑term execution risk. AnaptysBio Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: Analysts raised targets and ratings: Barclays moved to Overweight with a $79 PT and H.C. Wainwright raised its PT to $66 with a Buy — these upgrades increase investor confidence and provide fresh upside reference points. Benzinga Coverage ANAB PT Raised to $66 at H.C. Wainwright
• Positive Sentiment: Commercial upside from partner GSK: GSK reported strong Jemperli sales growth (~>13% QoQ to $343M in Q4), which implies meaningful and growing royalty flows to AnaptysBio under certain scenarios; management reiterated milestone/royalty expectations. Anaptys Provides Update on Business Separation and Announces Q4 and FY2025 Results
• Neutral Sentiment: Reported short‑interest data in recent feeds appears inconsistent (zero/NaN values and 0.0 days to cover) and likely not meaningful; no clear short squeeze signal from these reports. Market data / short interest summary
• Negative Sentiment: Despite the beat, the company still reported a negative net margin and an extremely negative return on equity (large historical losses reflected in ROE), signaling underlying profitability and capital‑efficiency issues that could temper valuation until the spin‑off and royalty streams fully materialize. Q4/FY2025 Press Release

Institutional Trading of AnaptysBio

Hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of AnaptysBio by 940.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 1,383 shares during the last quarter. Invesco Ltd. raised its position in AnaptysBio by 192.6% during the fourth quarter. Invesco Ltd. now owns 124,006 shares of the biotechnology company’s stock valued at $6,012,000 after purchasing an additional 81,625 shares during the period. Mackenzie Financial Corp bought a new stake in shares of AnaptysBio in the 4th quarter valued at approximately $1,166,000. XTX Topco Ltd lifted its stake in shares of AnaptysBio by 113.3% in the 4th quarter. XTX Topco Ltd now owns 38,637 shares of the biotechnology company’s stock valued at $1,873,000 after purchasing an additional 20,526 shares during the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of AnaptysBio in the 4th quarter worth approximately $215,000.

AnaptysBio Trading Up 12.8%

The company has a 50-day moving average price of $49.81 and a two-hundred day moving average price of $38.50. The stock has a market cap of $1.65 billion, a P/E ratio of -21.13 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The company had revenue of $108.25 million during the quarter, compared to the consensus estimate of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. As a group, equities analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has initiated a stock buyback program on Friday, November 21st that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.